

PROGRAMME
SYMPOSIUM DAY 1

NATIONAL CANCER CENTRE SINGAPORE,
LECTURE THEATRE, LEVEL 1

29 August 2025

0900 - 1000	DAY 1 REGISTRATION	
1000 - 1010	<u>Welcome Address</u>	
	<u>Focus on real-world lymphoma care issues in Asia and strategies to tackle them (PART I)</u> SESSION CHAIR: Dr Lawrence Ng & Dr Jason Chan	
1010 - 1040	<u>AYA care in Lymphoma</u> Dr Eileen Poon	
1040 - 1110	<u>Application of Geriatric Oncology in Lymphoma</u> Dr Lawrence Ng	
1110 - 1130	<u>Lymphoma care in Brunei – challenging cases of common lymphomas</u> Dr Noorainun Yusof	
1130 - 1300	<u>GILEAD/KITE - INDUSTRY LUNCH SYMPOSIUM @ NCCS LT</u> “Navigating the Complexity of An Evolving Treatment Landscape in R/R Lymphomas” With Dr Ahmad Alsaeed	LUNCH
	<u>Focus on real-world lymphoma care issues in Asia and strategies to tackle them (PART II)</u> SESSION CHAIRS: Dr Lawrence Ng & Dr Ong Choon Kiat	
1300 - 1320	<u>Advancing BTKi Therapy for MZL & FL Patients: From Clinical Trials to Real-World Impact</u> Dr Yuqin Song	
1320 - 1340	<u>Advancing DLBCL treatment with Bispecifics</u> Dr Philip Thompson	
1340 - 1400	<u>Advancing lymphoma care through research In Indonesia</u> Dr Anna Mira Lubis	
1400 - 1420	<u>Tackling lymphomas in the Philippines</u> Dr Jay Datukan	
1420 - 1430	Q&A Session	
1430 - 1530	COFFEE BREAK & POSTER VIEWING	
1530 - 1545	<u>Special Encore Abstracts</u> Dr Yuqin Song: Five-Year Analysis of an Asia Subpopulation with Previously Untreated DLBCL Confirms Pola-R-CHP Benefit on Outcomes: The POLARIX Study	
1545 - 1600	Dr Won Seog Kim: Mosunetuzumab plus polatuzumab vedotin is superior to R-GemOx in transplant-ineligible patients with R/R LBCL: primary results of the Phase III SUNMO trial	
1600 - 1700	<u>Case-based discussions/Mini-oral (submitted and selected based on merit)</u> Session chairs and Panels: Dr Jason Chan, Dr Gan Gin Gin & Dr Ong Choon Kiat	
1700	<u>Closing Address</u>	

PROGRAMME

SYMPOSIUM DAY 2

NATIONAL CANCER CENTRE SINGAPORE,
LECTURE THEATRE, LEVEL 1

 30 August 2025 

0900 - 1000	DAY 2 REGISTRATION	
	SCIENTIFIC SESSION 1 SESSION CHAIRS: Dr Ong Choon Kiat	
1000 - 1030	Opening Plenary: ESMO Clinical Practice Guidelines for Peripheral T-cell Lymphoma Dr Francesco D’Amore	
1030 - 1100	The Evolving Landscape of Bispecific Antibodies in RR DLBCL Dr Chieh-Lin Teng	
1100 - 1130	Updates on CAR-T cell therapy in DLBCL Dr Koji Izutsu	
1130 - 1200	Evolving Landscape of Advanced stage cHL: Optimising Treatment Outcomes with Expert Insights Dr Justin Ferdinandus	
1200 - 1300	LUNCH WITH POSTER SESSION	
	SCIENTIFIC SESSION 2 SESSION CHAIR: Dr Jason Chan and Dr Ong Choon Kiat	Leukemia and Lymphoma Foundation Breakout Session
1300 - 1330	Updates on 1L Mantle Cell Lymphoma Treatment Dr Alexey Danilov	From Survivor to Thriver: Navigating Work After Cancer Ms. Candice Chiew Leukemia and Lymphoma Foundation
1330 - 1400	Management of Relapsed/refractory Mantle Cell Lymphoma Dr Dok Hyun Yoon	
1400 - 1430	Novel therapies in R/R PTCL Dr Yuqin SONG	
1430 - 1505	Updates on CLL care in Asia Dr Eric Tse	
1500 - 1530	COFFEE BREAK	
	SCIENTIFIC SESSION 3 Session Chairs: Dr Jason Chan and Dr Ong Choon Kiat	
1530 - 1600	Molecular pathobiology of nodal NK/T cell lymphoma Dr Siok Bian NG	
1600 - 1630	Priming with DNMT inhibitors potentiates PD-1 immunotherapy by triggering viral mimicry in relapsed/refractory NK/T-cell lymphoma Dr Jing Tan	
1630 - 1700	Immune Checkpoint Inhibition in NK/T-cell lymphoma Dr Won Seog Kim	
1700	Closing Address	

PROGRAMME

EDUCATION PRECEPTORSHIP

NATIONAL CANCER CENTRE SINGAPORE,
CONFERENCE ROOM 21-9



31 August 2025



T-Cell Lymphoma	0800 - 0845	Registration and breakfast
	0850 - 0900	Short individual quiz
	0900 - 0945	<u>Case discussion on front line treatment of PTCL / NKTL</u>
	0945 - 1000	<u>Faculty summary on frontline treatment of PTCL/ NKTL</u>
	1000 - 1045	<u>Relapsed refractory T cell lymphoma – Participant case discussions (2 cases) MDT with participants/ faculty.</u>
	1045 - 1100	<u>Relapsed PTCL/NKTL – Faculty summary and what is in the horizon in 2025?</u>
	1100 - 1125	TEA BREAK
T- Cutaneous Lymphoma	1130 - 1145	<u>Cutaneous treatment options for T cell lymphoma with a focus on MF</u>
	1145 - 1200	<u>Diagnostic challenges in cutaneous lymphomas and MF</u>
	1215 - 1230	<u>Systemic treatment of cutaneous T-cell lymphoma – Oncologist perspective</u>
	1230 - 1315	<u>Interactive case discussions (with inter-table quiz)</u>
	1315 - 1355	LUNCH
CAR-T and Bispecific Antibodies	1400 - 1445	<u>Lessons on patient selection for CAR-T therapy – Faculty-led discussions (2 cases) MDT with participants/ faculty.</u>
	1445 - 1500	<u>Participant case presentation 1 – acute toxicity of CAR-T/bispecific therapies</u>
	1500 - 1515	<u>Management of acute toxicities of CAR-T and bispecific antibody therapies</u>
	1515 - 1530	<u>CAR-T therapies - Nursing and operations perspectives</u>
	1530 - 1545	<u>Participant case presentation 2 – infective complications of CAR-T/bispecific therapies</u>
	1545 - 1600	<u>Management of infective complications</u>
	1600 - 1620	<u>Q&A by Participants</u>
	1620 - 1630	<u>Closing + Final individual quiz</u>